Management of High-Risk MDS: Where Do We Stand? CME credits / Sharon Rawet Lederer Open to access this content Management of High-Risk MDS: Where Do We Stand? Read More »
My Story and Advocacy Efforts – Tuesday, June 3, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content My Story and Advocacy Efforts – Tuesday, June 3, 2025 Read More »
Refractoriness to Platelets Transfusion: How to Manage? – Thursday, May 22, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Refractoriness to Platelets Transfusion: How to Manage? – Thursday, May 22, 2025 Read More »
To Pee or Not to Pee: Prine Testing in Myeloma Response Evaluations – Monday, May 5, 2025 CME credits / Sharon Rawet Lederer Open to access this content To Pee or Not to Pee: Prine Testing in Myeloma Response Evaluations – Monday, May 5, 2025 Read More »
How I Manage Iron Overload in the Hematopoietic Cell Transplantation Setting | Blood | American Society of Hematology – Wednesday, April 23, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content How I Manage Iron Overload in the Hematopoietic Cell Transplantation Setting | Blood | American Society of Hematology – Wednesday, April 23, 2025 Read More »
Role of frailty and comorbidities in allo-SCT – Thursday, April 17, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Role of frailty and comorbidities in allo-SCT – Thursday, April 17, 2025 Read More »
IACH Roundtable Debate – Transplant at 65+: A Still Valid Strategy or a Risk We Should Retire? – Monday, April 7, 2025 Uncategorized / Yaniv Kalif Open to access this content IACH Roundtable Debate – Transplant at 65+: A Still Valid Strategy or a Risk We Should Retire? – Monday, April 7, 2025 Read More »
IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 CME credits / Adam Barkay Open to access this content IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 Read More »
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor – Tuesday, March 4, 2025 Uncategorized / Adam Barkay Open to access this content PTCy-based graft-versus-host disease prophylaxis for matched sibling donor – Tuesday, March 4, 2025 Read More »
Pioneers in Hematology: Dr Thierry Facon – Monday, January 6, 2025 Uncategorized / Adam Barkay Open to access this content Pioneers in Hematology: Dr Thierry Facon – Monday, January 6, 2025 Read More »
